

Tepotinib Treatment in Patients With *MET* Exon 14–Skipping Non–Small Cell Lung Cancer

Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

Julien Mazieres, MD, PhD; Paul K. Paik, MD; Marina C. Garassino, MD; Xiuning Le, MD; Hiroshi Sakai, MD; Remi Veillon, MD; Egbert F. Smit, MD, PhD; Alexis B. Cortot, MD, PhD; Jo Raskin, MD; Santiago Viteri, MD; Yi-Long Wu, MD; James C. H. Yang, MD; Myung-Ju Ahn, MD; Rui Ma, MD; Jun Zhao, MD; Aurora O'Brate, PhD; Karin Berghoff, MD, PhD; Rolf Bruns, MSc; Gordon Otto, MD, PhD; Andreas John, MD; Enriqueta Felip, MD, PhD; Michael Thomas, MD

[+ Supplemental content](#)

IMPORTANCE *MET* inhibitors have recently demonstrated clinical activity in patients with *MET* exon 14 (*MET*ex14)-skipping non–small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches.

OBJECTIVE To assess the long-term efficacy and safety of tepotinib, a potent and highly selective *MET* inhibitor, in patients with *MET*ex14-skipping NSCLC in the VISION study.

DESIGN, SETTING, AND PARTICIPANTS The VISION phase 2 nonrandomized clinical trial was a multicohort, open-label, multicenter study that enrolled patients with *MET*ex14-skipping advanced/metastatic NSCLC (cohorts A and C) from September 2016 to May 2021. Cohort C (>18 months' follow-up) was an independent cohort, designed to confirm findings from cohort A (>35 months' follow-up). Data cutoff was November 20, 2022.

INTERVENTION Patients received tepotinib, 500 mg (450 mg active moiety), once daily.

MAIN OUTCOMES AND MEASURES The primary end point was objective response by independent review committee (RECIST v1.1). Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.

RESULTS Cohorts A and C included 313 patients (50.8% female, 33.9% Asian; median [range] age, 72 [41–94] years). The objective response rate (ORR) was 51.4% (95% CI, 45.8%–57.1%) with a median (m)DOR of 18.0 (95% CI, 12.4–46.4) months. In cohort C (n = 161), an ORR of 55.9% (95% CI, 47.9%–63.7%) with an mDOR of 20.8 (95% CI, 12.6–not estimable [NE]) months was reported across treatment lines, comparable to cohort A (n = 152). In treatment-naïve patients (cohorts A and C; n = 164), ORR was 57.3% (95% CI, 49.4%–65.0%) and mDOR was 46.4 (95% CI, 13.8–NE) months. In previously treated patients (n = 149), ORR was 45.0% (95% CI, 36.8%–53.3%) and mDOR was 12.6 (95% CI, 9.5–18.5) months. Peripheral edema, the most common treatment-related adverse event, occurred in 210 patients (67.1%) (35 [11.2%] experienced grade ≥3 events).

CONCLUSIONS AND RELEVANCE The findings from cohort C in this nonrandomized clinical trial supported the results from original cohort A. Overall, the long-term outcomes of VISION demonstrated robust and durable clinical activity following treatment with tepotinib, particularly in the treatment-naïve setting, in the largest known clinical trial of patients with *MET*ex14-skipping NSCLC, supporting the global approvals of tepotinib and enabling clinicians to implement this therapeutic approach for such patients.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT02864992](https://clinicaltrials.gov/ct2/show/study/NCT02864992)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Julien Mazieres, MD, PhD, Service de pneumologie, Hôpital Larrey, CHU de Toulouse, 31000 Toulouse, France (mazieres.j@chu-toulouse.fr).

JAMA Oncol. 2023;9(9):1260–1266. doi:[10.1001/jamaoncol.2023.1962](https://doi.org/10.1001/jamaoncol.2023.1962)
Published online June 4, 2023. Corrected on July 20, 2023.

Cohort A from the phase 2 VISION nonrandomized clinical trial demonstrated robust and durable clinical activity with tepotinib in patients with *MET* exon 14 (*MET*ex14)-skipping NSCLC,¹⁻³ based on which, tepotinib was approved for use in several countries globally, including by the US Food and Drug Administration (FDA).

Herein, we report follow-up analysis of the independent similar findings from cohort C of the VISION trial along with the combined cohorts A and C outcomes after at least 18 months of follow-up.

Methods

The trial protocol and analysis plan are in [Supplement 1](#). VISION ([NCT02864992](#)) was a phase 2, single-arm, open-label, multicenter nonrandomized clinical trial of tepotinib in patients with *MET*ex14-skipping advanced/metastatic NSCLC (cohorts A and C). Cohort C (enrollment: August 2019-May 2021) was an independent cohort, designed to confirm findings from cohort A (enrollment: September 2016-December 2019).

Patients with advanced *EGFR/ALK* wild-type and *MET*ex14-skipping NSCLC detected by tissue (TBx) and/or liquid biopsy (LBx) using next-generation sequencing, received tepotinib, 500 mg (450 mg active moiety), once daily. The primary end point was objective response by independent review committee (IRC) using RECIST v1.1. Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Predefined analysis sets for all end points included *MET*ex14-skipping detection by TBx (T positive), LBx (L positive), and T positive and/or L positive.¹

An exploratory analysis using modified RANO-BM criteria assessed intracranial activity in patients with brain metastases (BM) and 1 or more evaluable postbaseline tumor assessments. Data cutoff for all analyses was November 20, 2022, except RANO-BM (data cutoff: February 20, 2022). For further details, see eMethods in [Supplement 2](#).

Results

Patients and Efficacy

Cohorts A and C included 313 patients (median [range] age, 72 [41-94] years; 159 [50.8%] female, 106 [33.9%] Asian, 149 [47.6%] smoking history, 231 [73.8%] ECOG PS 1, 252 [80.5%] adenocarcinoma; eTable 1 and eFigure 1 in [Supplement 2](#)). Patients in cohort C (n = 161) had more than 18 months' follow-up, and patients in cohort A (n = 152) had more than 35 months' follow-up. Median (range) follow-up was 32.6 (0.3-71.9) months across cohorts A and C. Overall, the objective response rate (ORR) was 51.4% (95% CI, 45.8%-57.1%) with a median (m) DOR of 18.0 (95% CI, 12.4-46.4) months, mPFS of 11.2 (95% CI, 9.5-13.8) months, and mOS of 19.6 (95% CI, 16.2-22.9) months (Table).

Baseline characteristics were broadly consistent between cohorts, with higher proportions of Asian (68 [42.2%] vs 38 [25.0%]), treatment-naïve (95 [59.0%] vs 69 [45.4%]),

Key Points

Question Does the long-term follow-up analysis of the VISION nonrandomized clinical trial demonstrate good clinical outcomes with tepotinib in patients with *MET* exon 14 (*MET*ex14)-skipping non-small cell lung cancer (NSCLC)?

Findings In the 18-month follow-up from cohort C (n = 161), objective response rate (ORR) was 55.9% and median duration of response (mDOR) was 20.8 months across treatment lines, supporting previous data from cohort A (n = 152). Across cohorts A and C, ORR was 57.3% with an mDOR of 46.4 months in treatment-naïve patients (n = 164).

Meaning This large nonrandomized clinical trial of patients with *MET*ex14-skipping NSCLC supports global approvals of tepotinib, enabling clinicians to implement these therapeutic approaches.

and patients with T-positive *MET*ex14-skipping detection (120 [74.5%] vs 88 [57.9%]) enrolled in cohort C vs A (eTable 2 in [Supplement 2](#)). With an ORR of 55.9% (95% CI, 47.9%-63.7%) and an mDOR of 20.8 (95% CI, 12.6-not estimable [NE]) months, these follow-up outcomes of longer than 18 months for cohort C are consistent with those from its primary analysis (>9 months' follow-up),⁴ and were improved compared with primary analysis results for cohort A (>9 months' follow-up),¹ but mostly comparable to those reported herein with longer-term follow-up (>35 months' follow-up; eTable 3, eFigure 2 in [Supplement 2](#)).

In cohorts A and C, 164 patients were treatment-naïve and 149 were pretreated. Baseline characteristics were broadly consistent; however, the treatment-naïve subgroup had a higher proportion of White patients and patients with smoking history, as well as higher baseline tumor load (eTable 1 in [Supplement 2](#)).

In treatment-naïve patients (n = 164), ORR was 57.3% (95% CI, 49.4%-65.0%) and mDOR was 46.4 (95% CI, 13.8-NE) months (Table, [Figure 1](#)). Most treatment-naïve patients had T-positive *MET*ex14-skipping detection (n = 111), and time-dependent end points were longer in this subset. Treatment-naïve T-positive ORR was 58.6% (95% CI, 48.8%-67.8%) with an mDOR of 46.4 (95% CI, 15.2-NE) months, mPFS of 15.9 (95% CI, 11.0-49.7) months, and mOS of 29.7 (95% CI, 18.8-NE) months (Table; eFigure 3 in [Supplement 2](#)). In cohort C, outcomes in treatment-naïve patients with T-positive *MET*ex14-skipping detection (n = 69) were further improved, with an ORR of 65.2% (95% CI, 52.8%-76.3%), mPFS of 16.5 (95% CI, 11.0-NE) months, and mOS of 28.5 (95% CI, 14.1-NE) months; mDOR was not reached (95% CI, 10.4-NE).

In pretreated patients (n = 149), ORR was 45.0% (95% CI, 36.8%-53.3%) and mDOR was 12.6 (95% CI, 9.5-18.5) months. In second-line patients with 1 prior therapy (n = 92), ORR was 45.7% (95% CI, 35.2%-56.4%) and mDOR was 12.6 (95% CI, 8.3-18.5) months (eTable 4 in [Supplement 2](#)). Pretreated patients with T-positive *MET*ex14-skipping detection had slightly improved outcomes in the time-dependent end points. Patients with L-positive *MET*ex14-skipping detection had a similar ORR (treatment-naïve patients, 58.9%; 95% CI, 48.4%-68.9%, and pretreated-patients, 43.4%; 95% CI, 32.5%-54.7%), but a trend

Table. Outcomes Following Tepotinib Treatment in Cohorts A and C According to Line of Therapy^a

Outcome	Overall			Treatment naive			Previously treated		
	T positive and/or L positive (n = 313)	T positive (n = 208)	L positive (n = 178)	T positive and/or L positive (n = 164)	T positive (n = 111)	L positive (n = 95)	T positive and/or L positive (n = 149)	T positive (n = 97)	L positive (n = 83)
ORR ^b , % (95% CI)	51.4 (45.8-57.1)	54.3 (47.3-61.2)	51.7 (44.1-59.2)	57.3 (49.4-65.0)	58.6 (48.8-67.8)	58.9 (48.4-68.9)	45.0 (36.8-53.3)	49.5 (39.2-59.8)	43.4 (32.5-54.7)
DCR, % (95% CI)	76.0 (70.9-80.7)	80.8 (74.7-85.9)	71.9 (64.7-78.4)	78.7 (71.6-84.7)	83.8 (75.6-90.1)	75.8 (65.9-84.0)	73.8 (66.0-80.7)	78.4 (68.8-86.1)	67.5 (56.3-77.4)
DOR Median (95% CI), mo	18.0 (12.4-46.4)	18.0 (10.8-46.4)	15.2 (9.7-33.6)	46.4 (13.8-NE)	46.4 (15.2-NE)	19.4 (8.3-NE)	12.6 (9.5-18.5)	12.4 (8.3-18.0)	12.4 (8.4-33.6)
Events, No. (%)	70 (43.5)	49 (43.4)	45 (48.9)	33 (35.1)	21 (32.3)	25 (44.6)	37 (55.2)	28 (58.3)	20 (55.6)
PFS Median (95% CI), mo	11.2 (9.5-13.8)	13.7 (11.0-17.1)	8.9 (7.8-11.0)	12.6 (9.7-17.7)	15.9 (11.0-49.7)	10.3 (8.0-16.5)	11.0 (8.2-13.7)	11.5 (8.2-14.7)	8.2 (5.7-11.0)
Events, No. (%)	165 (52.7)	101 (48.6)	107 (60.1)	81 (49.4)	50 (45.0)	53 (55.8)	84 (56.4)	51 (52.6)	54 (65.1)
OS Median (95% CI), mo	19.6 (16.2-22.9)	22.9 (18.8-28.5)	17.6 (12.6-21.3)	21.3 (14.2-25.9)	29.7 (18.8-NE)	17.6 (10.4-23.7)	19.3 (15.6-22.3)	20.4 (17.0-25.5)	16.2 (12.0-21.0)
Events, No. (%)	200 (63.9)	120 (57.7)	126 (70.8)	98 (59.8)	55 (49.5)	64 (67.4)	102 (68.5)	65 (67.0)	62 (74.7)
12-mo rate, % (95% CI)	72 (59-81)	75 (59-86)	68 (52-80)	65 (57-72)	74 (64-81)	59 (49-68)	68 (59-75)	72 (62-80)	60 (48-70)
24-mo rate, % (95% CI)	48 (35-59)	54 (37-68)	47 (31-61)	44 (36-52)	55 (44-64)	39 (29-49)	38 (30-46)	42 (32-52)	33 (23-43)

Abbreviations: DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; NE, not estimable.

^a T positivity was determined by detection of *MET*14 skipping in tissue biopsy

sample; L positivity by detection of *MET*14 skipping in liquid biopsy sample.

^b One treatment-naïve patient had a complete response; all other objective responses were partial responses.

toward shorter DOR, PFS, and OS (eFigure 4 in [Supplement 2](#)). Tumor shrinkage was observed in more than 90% of patients irrespective of treatment lines ([Figure 2](#)).

Of 57 patients in cohorts A and C with known baseline BM, systemic ORR per RECIST v1.1, accounting for intracranial and extracranial lesions, was 56.1% (95% CI, 42.4%-69.3%) (eTable 5 in [Supplement 2](#)). Among 15 patients with BM target lesions evaluable by RANO-BM (12 patients had received prior brain radiotherapy), intracranial ORR was 66.7% (95% CI, 38.4%-88.2%) (eTable 6 in [Supplement 2](#)). Five patients without baseline BM developed BM during treatment (per RECIST v1.1 by IRC).

Safety

In cohorts A and C, treatment-related AEs (TRAEs) occurred in 287 (91.7%) patients, and were grade 3 or higher in 109 (34.8%); 105 (33.5%) had dose reduction and 46 (14.7%) discontinued due to TRAEs (eTable 7 in [Supplement 2](#)). Peripheral edema was the most common TRAE (210 [67.1%]), with 35 (11.2%) experiencing grade 3 or higher peripheral edema. Other TRAEs occurring in more than 20% of patients included hypoalbuminemia (74 [23.6%]), nausea (73 [23.3%]), diarrhea (70 [22.4%]), and blood creatinine level increase (69 [22.0%]), and were mostly grades 1 to 2.

Discussion

Outcomes from the independent cohort C of the VISION trial supported the positive outcomes of tepotinib first reported in cohort A,¹ which now has follow-up of more than 35 months. With updated results from a larger patient population, ORR increased, particularly in treatment-naïve patients with T-positive *MET*14-


skipping detection with an ORR of 58.6%, compared with the previously reported ORR of 46%.¹ Tepotinib demonstrated clinically meaningful outcomes both in treatment-naïve and pretreated patients with *MET*14-skipping NSCLC, particularly when considering outcomes with nontargeted therapies.^{5,6} Consistency in PFS between treatment-naïve and pretreated patients has persisted with the larger population and increased follow-up duration. These data, and data from other studies,⁶⁻⁸ support the use of *MET* inhibitors across therapy lines for patients with *MET*14-skipping NSCLC.

Importantly, the VISION trial allowed enrollment based on prospective testing by TBx (associated with higher sensitivity and considered the gold standard⁹) and/or LBx. Both patients with T-positive and L-positive *MET*14-skipping detection had clinically meaningful outcomes for patients treated with tepotinib. Using LBx, being less invasive than TBx,⁹ enabled enrollment of a large population of patients who did not have TBx results. However, because LBx has limited sensitivity in low-ctDNA-shedding tumors and low tumor burden,⁹ it may have selected patients with a worse prognosis due to higher tumor burden and/or ctDNA shedding.⁹ This could explain the observations that patients with T-positive *MET*14-skipping detection had longer time-dependent end points, and cohort C treatment-naïve patients (with more patients with T-positive *MET*14-skipping detection) had better outcomes than those in cohort A.

In patients with baseline BM, tepotinib demonstrated robust systemic and intracranial outcomes, which had comparable clinical benefit to patients without baseline BM. Aligned with guidelines,¹⁰ this supports the use of brain-penetrating *MET* inhibitors, providing a systemic therapy alternative to radiation.

Tepotinib was generally well tolerated with a low proportion of TRAEs leading to discontinuation. The most common

Figure 1. Outcomes Following Tepotinib Treatment in Cohorts A and C



TRAE, peripheral edema (a class effect of MET inhibitors⁵⁻⁷), was mostly mild to moderate.


Limitations

The VISION study was a nonrandomized clinical trial. The confirmatory cohort C analysis was also limited by positive results in cohort A being reported while enrollment was ongoing, which may have encouraged recruitment of patients in a better clinical condition into cohort C.

Conclusion

In this long-term follow-up analysis of data from the VISION nonrandomized clinical trial, tepotinib demonstrated robust and durable clinical outcomes across therapy lines in the largest known clinical trial of patients with *MET*ex14-skipping NSCLC, enrolled based on TBx or LBx. Efficacy was clinically meaningful in patients with 1 or more prior therapies, and par-

Figure 2. Change in Sum of Longest Diameters Between Baseline and Best Postbaseline Assessment by IRC in Cohorts A and C



A, Treatment-naïve patients.
B, Previously treated patients.
Four treatment-naïve and 4 previously treated patients are not shown due to baseline/on-treatment measurement not being available. IRC indicates independent review committee; L⁺, positive detection of *MET*ex14 skipping in liquid biopsy sample; T⁺, positive detection of *MET*ex14 skipping in tissue biopsy sample.

ticularly in treatment-naïve patients. This analysis of results from the VISION trial supports global approvals of tepotinib,

enabling clinicians to implement this therapeutic approach for patients with *MET*ex14-skipping NSCLC.

ARTICLE INFORMATION

Accepted for Publication: April 10, 2023.

Published Online: June 4, 2023.

doi:10.1001/jamaoncol.2023.1962

Open Access: This is an open access article distributed under the terms of the [CC-BY-NC-ND License](#). © 2023 Mazieres J et al. *JAMA Oncology*.

Correction: This article was corrected on July 20, 2023, to fix errors in the conflicts of interest section and to update some of the authors affiliations. In addition, there was 1 mark missing in the L-positive section of Figure 2, panel B.

Author Affiliations: CHU de Toulouse, Université Paul Sabatier, Toulouse, France (Mazieres); Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York (Paik); Department of Medicine, Weill Cornell Medical College, New York, New York (Paik); Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Garassino); Now with Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois (Garassino); Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center,

Houston (Le); Department of Thoracic Oncology, Saitama Cancer Center, Kitaadachi-gun, Japan (Sakai); Now with Department of Thoracic Oncology, Ageo Central General Hospital, Saitama, Japan (Sakai); CHU Bordeaux, service des maladies respiratoires, Bordeaux, France (Veillon); Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands (Smit); Now with Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, the Netherlands (Smit); Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, Lille, France (Cortot); Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZ), Edegem, Belgium (Raskin); Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Grupo Quiron Salud, Barcelona, Spain (Viteri); Now with UOMI cancer center, Clínica Mi NovAlianza, Lleida, Spain (Viteri); Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China (Wu); Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan (Yang); Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan

University School of Medicine, Seoul, Korea (Ahn); Medical Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China (Ma); Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China (Zhao); Global Medical Affairs, the healthcare business of Merck KGaA, Darmstadt, Germany (O'Brate); Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany (Berghoff); Department of Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany (Bruns); Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany (Otto, John); Department of Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (Felip); Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany (Thomas); Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany (Thomas).

Author Contributions: Prof Mazieres had full access to all of the data in the study and takes

responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Le, Smit, Wu, Ma, O'Brate, Bruns, Otto, Johnne.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Mazieres, Paik, Le, Sakai, Smit, Cortot, O'Brate, Bruns, Otto, Johnne.

Critical revision of the manuscript for important intellectual content: Mazieres, Paik, Garassino, Le, Sakai, Veillon, Smit, Cortot, Raskin, Viteri, Wu, Yang, Ahn, Ma, Zhao, O'Brate, Berghoff, Bruns, Otto, Felip, Thomas.

Statistical analysis: Le, Bruns.

Administrative, technical, or material support: Veillon, Smit, Wu, Ma, Zhao, O'Brate, Otto, Johnne, Thomas.

Supervision: Garassino, Ahn, Ma, Berghoff, Otto, Johnne, Felip.

Other: writing, reviewing, and editing; validation: Mazieres.

Conflict of Interest Disclosures: Dr Mazieres reported personal fees/advisory board membership from Roche and Bristol Myers Squibb, and AstraZeneca, advisory board membership and research funding (institution), personal fees/advisory board membership from Pfizer, Novartis, Amgen, Takeda, Daiichi Sankyo, the healthcare business of Merck KGaA, Darmstadt, Germany, grants/funding (institution) from Roche/Genentech, Bristol Myers Squibb, and AstraZeneca outside the submitted work. Dr Paik reported advisory board funds, institutional research funding, and/or personal fees from EMD Serono, Takeda DSMC, Janssen, Xencor, Boehringer Ingelheim, CrownBio, Mirati, Calithera, and Novartis outside the submitted work. Dr Garassino reported personal fees from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study; grants and personal fees from AstraZeneca, personal fees from the healthcare business of Merck KGaA, Darmstadt, Germany, Bayer, BMS, AbbVie, Takeda, Janssen, Roche, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novartis, and Blueprint outside the submitted work. Dr Le reported personal/consulting fees from EMD Serono during the conduct of the study; personal or consulting fees from AstraZeneca, Spectrum Pharmaceuticals, Novartis, Eli Lilly, Boehringer Ingelheim, Janssen, Blueprint Medicines, Bayer, Albion, grants from ArriVent, Eli Lilly, Boehringer Ingelheim, Regeneron, and personal fees from AbbVie outside the submitted work. Dr Sakai reported personal fees from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study; personal fees from Bristol Myers Squibb and Chugai Pharma outside the submitted work. Dr Veillon reported research funding from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study; personal consulting fees from Janssen, personal speaker fees from BMS, Takeda, personal speaker bureau fees from Amgen, Sanofi, Roche, AstraZeneca, and travel fees from Pfizer Travel and Janssen outside the submitted work. Dr Smit reported institutional fees for advisory or consultancy services from Lilly, AstraZeneca, Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Merck & Co Oncology, Takeda, Bayer, Regeneron, Novartis, Daiichi Sankyo, Seattle Genetics, the healthcare business of Merck KGaA, Darmstadt, Germany; and receives research funding (to institution) from Boehringer Ingelheim,

Bayer, Roche/Genentech, AstraZeneca, and Bristol Myers Squibb. Dr Cortot reported the healthcare business of Merck KGaA, Darmstadt, Germany, clinical trial investigator fees during the conduct of the study; grants from the healthcare business of Merck KGaA, Darmstadt, Germany, personal fees from Novartis, Roche, Takeda, Amgen, nonfinancial support from Novartis and Amgen, personal fees from Pfizer, nonfinancial support from Pfizer, personal fees from Exelixis, InhaTarget, AbbVie, and grants from AbbVie outside the submitted work. Dr Raskin reported travel expenses from Roche, personal fees from Pfizer, Lilly, Boehringer Ingelheim, BMS, and the healthcare business of Merck KGaA, Darmstadt, Germany, outside the submitted work. Dr Viteri reported personal fees from the healthcare business of Merck KGaA, Darmstadt, Germany, AbbVie, BMS, AstraZeneca, Merck & Co, Roche, nonfinancial support from OSE Immunotherapeutics, personal fees from Janssen and Puma Biotechnology outside the submitted work. Dr Wu reported grants from AstraZeneca; BMS, Pfizer (grant to the institute), personal fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Hengrui, Merck & Co, Pfizer, Sanofi, and speaker fees from Roche outside the submitted work. Dr Yang reported institutional fees for advisory or consultancy services from Amgen, grants from AstraZeneca to conduct investigator-initiated study, institutional fees for advisory or consultancy services from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & Co, Novartis, personal fees from Novartis Committee for data safety, and institutional fees for advisory or consultancy services from Pfizer, Roche/Genentech, Takeda, Yuhan Pharmaceuticals, Janssen, Puma Technology, Gilead, and GSK outside the submitted work. Dr Ahn reported personal fees from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study; personal fees from AstraZeneca, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & Co, Yuhan, Takeda, Roche, Alpha pharmaceuticals, and Amgen outside the submitted work. Dr O'Brate reported employment from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study. Dr Otto reported personal fees from Merck KGaA, Darmstadt, Germany, employment at the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study. Dr Johnne reported employment and stock holdings from the healthcare business of Merck KGaA, Darmstadt, Germany, during the conduct of the study. Dr Felip reported grants from the healthcare business of Merck KGaA, Darmstadt, Germany (research funding to institution), and Fundación Merck Salud, a private nonprofit institution founded by the healthcare business of Merck KGaA, Darmstadt, Germany (research funding to institution) during the conduct of the study; consulting fees from Amgen, consulting fees, speaker fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F Hoffmann-La Roche, Janssen, Medical Trends, Medscape, Merck & Co, PeerVoice, Pfizer, Sanofi, Takeda, Touch Oncology, independent board membership at Grifols, consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche, GSK, Janssen, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & Co, Novartis,

Peptomyc, Pfizer, Sanofi, Takeda, and BerberBio, speaker fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, other from F Hoffmann La Roche, Janssen, Medical Trends, Medscape, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & CoPeerVoice, Pfizer, Sanofi, Takeda, and Touch Oncology outside the submitted work. Dr Thomas reported personal fees from AstraZeneca, Beigene, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Daiichi Sankyo, GSK, Janssen Oncology, Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & Co, Novartis, Pfizer, Roche, Sanofi, and Takeda outside the submitted work. No other disclosures were reported.

Funding/Support: The trial was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Role of the Funder/Sponsor: The healthcare business of Merck KGaA, Darmstadt, Germany, had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 3](#).

Additional Contributions: We thank the patients and their families, investigators, coinvestigators, and the study teams at all participating centers, as well as the healthcare business of Merck KGaA, Darmstadt, Germany. Medical writing assistance (funded by the healthcare business of Merck KGaA, Darmstadt, Germany) was provided by Pritha Bhunia of Syneos Health, UK.

REFERENCES

- Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. *N Engl J Med*. 2020;383(10):931-943. doi:10.1056/NEJMoa2004407
- Le X, Sakai H, Felip E, et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. *Clin Cancer Res*. 2022;28(6):1117-1126. doi:10.1158/1078-0432.CCR-21-2733
- Viteri S, Mazieres J, Veillon R, et al. 1286P Activity of tepotinib in brain metastases (BM): preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. *Ann Oncol*. 2020;31(suppl 4):S754-S840. doi:10.1016/j.annonc.2020.08.1600
- Thomas M, Garassino MC, Felip E, et al. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: primary analysis of the confirmatory VISION cohort C. *J Thorac Oncol*. 2022;17(9):S9-S10.
- Ernani V, Ganti AK. Immunotherapy in treatment naïve advanced non-small cell lung cancer. *J Thorac Dis*. 2018;10(suppl 3):S412-S421. doi:10.21037/jtd.2017.12.94
- Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nat Med*. 2020;26(1):47-51. doi:10.1038/s41591-019-0716-8
- Wolf J, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1

study. *J Clin Oncol*. 2021;39(Suppl 15):9020 [abstract and poster]. doi:10.1200/JCO.2021.39.15_suppl.9020

8. Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring *MET* exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. *Lancet Respir Med*. 2021;9(10):1154-1164. doi:10.1016/S2213-2600(21)00084-9

9. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2021;16(10):1647-1662. doi:10.1016/j.jtho.2021.06.017

10. Le Rhun E, Guckenberger M, Smits M, et al; EANO Executive Board and ESMO Guidelines Committee. Electronic address: [clinicalguidelines@](mailto:clinicalguidelines@esmo.org)

[esmo.org](https://www.esmo.org). EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. *Ann Oncol*. 2021;32(11):1332-1347. doi:10.1016/j.annonc.2021.07.016